Cianti C
Ospedale S. Spirito in Sassia, Roma, Italia.
Clin Ter. 2002 Mar-Apr;153(2):135-44.
To present an approach to the treatment of epithelial ovarian cancer.
A large number of studies in ovarian cancer have been reviewed.
Ovarian cancer is the most common fatal malignancy of the female genital tract. The high mortality is due to the fact that the most part of patients are diagnosed with advanced disease. Cytoreductive surgery followed by platinum-based chemotherapy is the standard therapeutic strategy for patients with advanced ovarian cancer. Postsurgical residual disease is the most important prognostic factor. The combination of Paclitaxel and Cisplatin or Carboplatin is currently accepted as the standard chemotherapy for advanced ovarian cancer. Second- look laparatomy should be reserved to patients enrolled in clinical trial. Resistant disease remain the major cause of relapse and death. Several drugs have been employed in second-line therapy; however, the responses are generally short and survival is poor.
Future research should include new drugs or new combination regimens to improve clinical outcomes and overall survival.
介绍一种上皮性卵巢癌的治疗方法。
回顾了大量关于卵巢癌的研究。
卵巢癌是女性生殖道最常见的致命恶性肿瘤。高死亡率是因为大部分患者被诊断为晚期疾病。细胞减灭术联合铂类化疗是晚期卵巢癌患者的标准治疗策略。术后残留病灶是最重要的预后因素。紫杉醇与顺铂或卡铂联合目前被公认为晚期卵巢癌的标准化疗方案。二次探查剖腹术应仅用于参加临床试验的患者。耐药性疾病仍然是复发和死亡的主要原因。几种药物已用于二线治疗;然而,反应通常短暂且生存率低。
未来的研究应包括新药或新的联合方案,以改善临床结局和总生存期。